ERBB2 and breast cancer: Consistent with this, when breast cancer patients were stratified based on ER, HER2, and KI67 expression (Additional file 1: Figure S1A), we noted that the impact of high DENND10 expression could be recognized at earlier time points (~ 25 months) in luminal B (characterized by high proliferation rates) and basal (HER2-/ER-) patients.